Lifecare ASA: Mandatory notification of trade

Reference is made to the stock exchange announcement published by Lifecare ASA (the “Company”) on 8 October 2024, regarding the commencement of the application period in the public retail offering (the “Offering”) of up to 1,000,000 new shares (the “Offer Shares”).

Hannibal Invest AS, a company closely associated with Hans Hekland, board member of the Company, has today applied for 5,000 shares in the Offering at an offer price of NOK 20 per Offer Share, subject to allocation by the Board of Directors upon expiry of the application period for the Offering. Please see the attached PDMR-form for further details.  

About us
Lifecare ASA is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare’s main focus is to bring the next generation of Continuous Glucose Monitoring (“CGM“) systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors (“NTR“) on the sensor body for read-out of pressure variations. Lifecare’s sensor technology is referred to as “Sencell” and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities Trading Act, §5-12. The information was submitted for publication at 2024-10-10 15:10 CEST.

Attachments
Lifecare ASA: Mandatory notification of trade
PDMR Attachment

Lifecare ASA: Mandatory notification of trade
PDMR Attachment